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Background 
Helicobacter pylori Infections 
H. pylori is a gram-negative, spiral-shaped bacteria1. This bacteria has different adaptations that
allow it to remain in the gastrointestinal tract, such as flagella to assist with resisting contractions 
produced by the small intestine1. H. pylori also produces an enzyme called urease, which alkalinizes the 
harsh, acidic environment in the stomach, making it a more habitable place to live1,2. H. pylori infections 
can cause serious problems for patients, starting with chronic gastritis or ulcers in the stomach, small 
intestine, or esophagus1-6. A seemingly benign infection can eventually progress to gastric lymphoma or 
cancer, and H. pylori is technically considered a carcinogen1-4,6-8. Infection is correlated with low 
socioeconomic status2-4,6,9, low education level3,9, and African American race3,4. H. pylori infection has a 
genetic component4 and is transmitted amongst families living in the same household1,9. Therefore, 
someone whose parent or sibling has had a gastric ulcer or stomach cancer caused by H. pylori is more 
likely to have H. pylori colonization1. 
 Diagnostic Testing for H. pylori 
There are three main objective methods used to diagnose a patient with an H. pylori infection. 
The first method, a urease breath test, is by far the most convenient method. This test measures urease 
activity produced by the bacteria. While noninvasive, inexpensive and convenient, follow-up results 
after treatment may have the potential to be falsely negative. If a patient has taken antibiotics and a 
proton-pump inhibitor <4 weeks before administration of the test, it may not be able to detect the small 
amount of resistant bacteria still present in the stomach1.   
Biopsy-based testing is usually done in the hospital setting. Biopsies involve an endoscopy 
procedure that obtains a sample from the stomach. This type of testing is considered the “gold 
standard” of diagnostic H. pylori testing1. Obtaining a sample of actual bacteria also allows the ability to 
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determine sensitivities to antibiotics. While biopsy-based testing is very specific, it only evaluates a small 
portion of the stomach and may not be completely sensitive to H. pylori presence. It is also invasive and 
expensive1.   
The other method of testing mentioned in the ACG guidelines is fecal antigen testing. Fecal 
antigen testing involves looking for the presence of antigens to H. pylori in the stool. This option is cost-
effective for many patients but is not used as widely as the urea breath test. Fecal antigen testing results 
can also be affected by antibiotic and proton-pump inhibitor (PPI) use so waiting at least four weeks 
after discontinuing antibiotics is crucial for an accurate result10.  
Treatment Options 
There are multiple treatment options for treating H. pylori infections, and most treatment 
options include two or more antibiotic classes in conjunction with a PPI2,4-5,8. The main workhorses of 
treating an H. pylori infection are the macrolide and fluoroquinolone (FQ) classes of antibiotics. 
Macrolides include erythromycin, clarithromycin, and azithromycin. Commonly used fluoroquinolones 
include levofloxacin and ciprofloxacin. The most recent American College of 
Gastroenterology (ACG) H. pylori treatment guidelines provide specific recommendations for using 
these antibiotics based on kidney function, previous antibiotic exposure, and whether or not the 
infection is a reoccurrence4. The most common regimens seen at St. Vincent’s primary care 
centers mimic the ACG guidelines and include the bismuth quadruple (bismuth subsalicylate, a PPI, 
tetracycline, and metronidazole) and clarithromycin triple (PPI, clarithromycin, and amoxicillin OR 
metronidazole) regimens. The ACG’s recommended first-line treatment for an initial H. pylori infection is 
specified in Table 1. 
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Table 1. Guideline-directed initial H. pylori treatment therapy4
Presence 
of true 
penicillin 
allergy 
Previous macrolide exposure 
Yes No 
Yes Bismuth quadruple 
Levofloxacin triple 
Levofloxacin sequential 
Bismuth quadruple 
Clarithromycin triple* 
Concomitant 
No Bismuth quadruple Clarithromycin tripleꝉ
Bismuth quadruple 
Bismuth quadruple: PPI + Bismuth subcitrate/subsalicylate + Tetracycline + Metronidazole x 10-14 days 
Clarithromycin triple: PPI + Clarithromycin + Amoxicillin OR Metronidazole x 14 days 
*with Amoxicillin
ꝉwith Metronidazole 
Levofloxacin triple: PPI + Levofloxacin + Amoxicillin x 10-14 days 
Levofloxacin sequential: PPI + Amoxicillin x 5-7 days, then add Levofloxacin + Nitroimidazole x an add’l 5-7 days 
Concomitant: PPI + Clarithromycin + Amoxicillin + Nitroimidazole x 3-10 days4 
Need for Study 
Antibiotic Resistance Overview 
Unfortunately, macrolides and fluoroquinolones are among the worst culprits for inducing 
antibiotic resistance, which has impacted the ability to successfully treat H. pylori. In fact, in 2017 the 
World Health Organization (WHO) named H. pylori a high priority bacterium for antibiotic research and 
development due to high rates of resistance2,11-12. Antibiotic resistance can arise when mutations occur 
in the genetic material of bacteria that change the way the bacteria respond to the antibiotic. In 
macrolides’ case, a mutation occurs at the ribosome (site that the drugs bind to) and decreases the 
macrolides’ affinity for the ribosome2,4-5,11,13-14. For fluoroquinolones, the bacteria develop DNA changes 
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in the enzyme that these drugs bind to (DNA gyrase) and limits binding ability of fluoroquinolones2,4,11,14. 
Eventually H. pylori’s ability to synthesize and replicate its DNA are diminished14. This can lead to 
infections that aren’t cured by first-choice regimens and the need to use less optimal, more expensive 
antibiotics with undesirable side effects arises. It has been shown that susceptibility of the bacteria to 
the antibiotic regimen is the greatest determinant of treatment success4-6,8. Metronidazole is also a 
medication commonly used for H. pylori that has significant worldwide resistance, but this project will 
not focus on these rates as this resistance can often be overcome by increasing the treatment dose or 
duration4,8,14. Amoxicillin and tetracycline (TCN) are also used commonly in H. pylori treatment 
regimens, but their resistance rates are consistently very low worldwide2,4,6,8,11,14 and will not be focused 
on in this project. 
 
Helicobacter pylori Resistance 
Resistance can occur by many mechanisms, such as the overuse and overprescribing of 
antibiotics. In general, it has been proven that countries who have high resistance rates have higher 
prescription antibiotic consumption8,14. When looking at the H. pylori organism specifically, it has 
previously been proven that H. pylori eradication rates are higher in patients who have previously 
received a macrolide5. As shown in Table 1, the most recent ACG guidelines recommend that if a patient 
has been exposed to a medication in the macrolide class of antibiotics that they should avoid using 
another macrolide, since there is a high probability that the H. pylori in their stomach will have 
developed resistance to it during the previous exposure4-6,11. There have been multiple studies that 
explore H. pylori’s increasing resistance rates around the world. The commonly accepted resistance rate 
threshold for a medication that indicates the highly resistant medication class should be avoided and 
another agent should be chosen is >15%4,6,8. Past this threshold, H. pylori treatment success rates 
significantly decline. 
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Worldwide resistance rates sorted by region were collected in a 2018 meta-analysis and can be 
found in Table 26. As shown in Table 2, many parts of the world have resistance rates greater than the 
accepted threshold for treating with clarithromycin or levofloxacin6. H. pylori contracted in a different 
part of the world may be more resistant to initial antibiotic treatment strategies used in the United 
States. Thus, it may be beneficial to take recent travel and home country into account when selecting an 
initial H. pylori treatment regimen. One region that was recognized for significant levels of H. pylori 
resistance is Latin America. While one meta-analysis shows the American region to have a resistance 
rate at or below the 15% threshold6 and another shows overall resistance rate in Latin America to be 
only 12%8, there is variety between actual countries. In 2007, the countries with the highest 
consumption of macrolides per capita were Venezuela, Argentina, and Chile8. The same three countries 
saw a significant increase in fluoroquinolone use over a ten-year period8. Peru had the highest 
prevalence of H. pylori resistance at 50%8. In contrast, Mexico, Uruguay, and Colombia saw decreases in 
their macrolide use8 and the lowest clarithromycin resistance rate was well below the threshold at 2% in 
Paraguay8. Given this wide variety of resistance rates among Latin America, each country’s resistance 
rates should be taken into consideration to determine whether clarithromycin or levofloxacin is 
appropriate for initial treatment. Along with differing resistance rates, there is a large part of the 
population that has increased activity of the enzyme that metabolizes the PPI component of treatment, 
CYP2C198. This may decrease the effectiveness of the PPI, as it is being cleared too fast to have a 
therapeutic effect. 
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Table 2. Primary Resistance Rates of Clarithromycin and Levofloxacin by World Region6 
Region Clarithromycin Resistance 
Rate 
Levofloxacin Resistance Rate 
Africa Region 
Cameroon, Congo, Senegal 
15% 14% 
Americas Region 
Argentina, Brazil, Canada, 
Colombia, Peru, USA 
10% 15% 
Eastern Mediterranean 
Region 
Egypt, Iran, Morocco, Pakistan, 
Saudi Arabia 
33% 19% 
European Region 
Austria, Belgium, Bulgaria, Croatia, 
France, Germany, Greece, 
Iceland, Ireland, Israel, Italy, 
Poland, Spain, Netherlands, 
Turkey, UK, 
Multicentric/International 
18% 11% 
Southeast Asia Region 
Bangladesh, Bhutan, India, 
Indonesia, Thailand 
10% 30% 
Western Pacific Region 
Australia, China, Japan, South 
Korea, Laos, Malaysia, New 
Zealand, Singapore, Taiwan, 
Vietanam 
34% 19% 
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While there is a good idea of resistance rates of other countries, there is not a good estimate of 
the resistance rates specific to the United States, let alone the Indianapolis patient population. The most 
recent study done by the Houston VA Medical Center reported resistance rates for clarithromycin to be 
16% and levofloxacin to be 31%16. 
 
Objectives 
Since resistance to H. pylori is such a significant problem worldwide and resistance rates are 
not well published in America, more definitive data is needed to determine whether St. Vincent’s 
prescribed regimens are truly resulting in successful eradication of H. pylori infections, and whether 
protocol to incorporate the risk of resistance as a treatment regimen determinant need to be 
formulated. The main objective of this project is to identify what percentage of H. pylori infections 
diagnosed at St. Vincent’s Family Medicine and Internal Medicine clinics are being successfully treated 
with current, guideline-directed therapy. The secondary objective of this project is to obtain a general 
understanding of H. pylori resistance rates to clarithromycin and levofloxacin in the Indianapolis area 
based on treatment failure rates. Any conclusions able to be drawn about local resistance and how 
Indianapolis compares to the rest of the world may help guide future treatment decisions among 
prescribers.   
 
Methods 
This project was a retrospective chart review that looks at past patient data from St. Vincent’s 
Internal Medicine and Family Medicine clinics. St. Vincent’s electronic medical record, Athena, was used 
for chart review. St. Vincent’s pharmacy services database, Enterprise, was used to obtain prescription 
filling information. All data was extracted to and managed using the Ascension installation of REDCap 
(Research Electronic Data Capture). REDCap provides a secure way to track data while ensuring proper 
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handling of personal identifying information (PHI)17,19. This project did not require an Institutional 
Review Board approval; instead, the project was approved by St. Vincent’s Quality Improvement 
Committee.  
 
 
Inclusion Criteria 
Patients in the review were > 18 years old at the time of diagnosis, patients at either St. 
Vincent’s Internal Medicine or Family Medicine clinics and were diagnosed with H. pylori in between the 
date range of February 1st, 2017 to August 31st, 2018. The beginning of this date range falls 
approximately one month after the most recent ACG guidelines were published. A patient list was 
generated using a query from Athena using the ICD codes B96.81 (H. pylori as the cause of diseases 
classified elsewhere), K29.70 (gastritis, unspecified, without bleeding) or A04.8 (bacterial infections 
intestinal).  
 
Data Collection  
Each patient’s labs, clinical documents, medications, fill history and relevant outside records 
were reviewed and pertinent patient information was documented in REDCap. This information was 
used to fill in a pre-written questionnaire; items on the questionnaire can be found in Table 3. These 
questions were written in yes-no format whenever possible; other choices were multiple choice and 
written response. For multiple choice answers, an “Other” category was given for treatment decisions 
that did not match pre-populated answers. 
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Table 3. Relevant Patient Data Components 
H. pylori diagnosis (Y/N)
Presence of allergy to any component of the treatment regimen 
Prescription for a macrolide or a fluoroquinolone in the last year 
Presence of drug interactions with patient’s existing medication list at start of regimen 
Type of H. pylori treatment regimen (clarithromycin triple, bismuth quadruple, etc.) 
Zip code patient lives in Indianapolis or within 25 miles of Indianapolis 
Recent travel outside the United States within 1 year and country of destination 
Diagnostic test used to diagnose H. pylori infection (Urea breath test, fecal antigen test, or 
biopsy-based test) 
Diagnosis date of H. pylori 
Methods of follow-up and timing in relation to completion of treatment regimen 
Presence of clinic visits starting 4 weeks after treatment completion with H. pylori symptoms or 
another positive diagnosis of H. pylori  
Whether or not the prescriptions were filled 
Whether or not the prescriptions were picked up by the patient 
Patient picked up medications prescribed for H. pylori (all, some, or none) 
What type of second line treatment regimen was prescribed, if applicable, and whether or not it was 
appropriate. 
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Whether or not the patient was diagnosed with H. pylori and diagnosis date of H. pylori were 
collected to exclude those who did not fit the criteria of the project. Presence of allergies to any 
component of the treatment regimen were collected to identify improper treatment initiation. It was 
also used to identify potential reasoning for failed treatment, since an allergic reaction could have 
potentially resulted in stopping the treatment regimen prematurely and/or result in a delay of infection 
resolution. Prior fluoroquinolone use is not mentioned in the ACG guidelines but was collected 
regardless to explore the possibility that prior use may impact successful therapy, since 
fluoroquinolones are another class of antibiotics that are notorious for high resistance rates. Zip code 
was collected to ensure the patient lives in Indianapolis or within a 25-mile radius. This ensures that the 
data collected will accurately reflect the typical Indianapolis patient population. Recent travel outside 
the United States within 1 year and to where was collected to determine whether the patient may be 
harboring H. pylori from other countries where resistance rates to clarithromycin or levofloxacin may be 
higher or lower than the appropriate threshold of >15%. Fill rates were determined by using Enterprise 
for patients who filled at St. Vincent’s Pharmacy and by looking at insurance claims for patients filling at 
an outside pharmacy. This was collected to assess whether the patient was truly taking the regimen that 
was prescribed. Choice of treatment regimen, prior macrolide use within one year, diagnostic testing 
methods, methods and timing of follow-up, and second-line treatment for failed treatment were 
collected to ensure recommendations made by the ACG guidelines were followed appropriately. Each 
patient’s home medication regimen charted on that day and the H. pylori treatment regimen prescribed 
was assessed using Lexicomp’s drug interaction report to assess any potential that therapy could be 
rendered less effective.  
Each individual patient was assessed by the researcher using the objective data above and the 
ACG guidelines as guidance and was sorted into “Failed,” “Successful,” or “Unknown Outcome” groups. 
Each patient was also determined to have received “Appropriate” or “Inappropriate” therapy.  The 
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“Inappropriate” group was further explored to try and determine potential protocol changes that may 
assist healthcare team members in improving H. pylori treatment. The “Failed” treatment group was 
assessed in tandem with their appropriateness of therapy to try and determine whether causes of 
failure stemmed from potential resistance to treatment or inappropriate therapy.  
 
Results 
Patient Characteristics 
There were 105 patient records that were populated through the EMR inquiry. Forty-one 
patients either received tests for H. pylori that resulted in a negative result or were diagnosed with a 
different gastric condition, such as gastritis. These patients were excluded from analysis. The remaining 
sixty-four patient records were analyzed. 
The mean age of the total population was 44.31 years old, with a standard deviation of 14.75 
years. The youngest patient in the group was 18.99 years and the oldest patient was 81.27 years. All 
patients initially identified through Athena lived in an address with a zip code that was within a 25-mile 
radius of Indianapolis (105 out of 105).  
Out of the 64 patients that were diagnosed with H. pylori, the urea breath test (UBT) was the 
most commonly used diagnostic test with 42 patients. There were 4 patients that were diagnosed using 
fecal antigen testing and 15 patients that were diagnosed using a biopsy-based test. Two patients were 
not tested and 1 patient’s record did not specify what test was given.  
There were 6 patients that had allergies to one or more medications in the treatment regimens. 
Five out of six patients had penicillin allergies documented; none received amoxicillin-containing 
regimens. One patient had a documented allergy to omeprazole; the first-line regimen contained 
pantoprazole instead and no adverse effects from the pantoprazole were documented.  
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An overwhelming 46 out of 64 patients required translator services, with the majority (32 out of 
46) speaking Spanish. There were a total of 10 different languages spoken amongst those needing 
translators. A complete breakdown of native languages can be found, along with additional analysis of 
patient population parameters, in Figure 1. 
Figure 1. 
Patient age   
Total 
Count 
(N) 
Missing Unique Min Max Mean StDev Sum 
Percentile 
0.05 0.10 0.25 0.50 Median 0.75 0.90 0.95 
105 0 (0.0%) 105 18.99 81.27 44.31 14.75 4,653.07 22.44 25.73 33.65 43.41 54.14 65.59 71.40 
 
Lowest values: 18.990123000472288, 19.414612666014133, 19.885532671216154, 21.829332566719373, 
22.094909546397258 
Highest values: 72.64214870941909, 74.97484547937329, 75.00507653590878, 76.32737154082561, 
81.27476950245385  
 
Figure 1., continued.  
Initial Diagnostic Testing                                                                        Native Languages 
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 Treatment 
 For brevity, regimens will be abbreviated; please see Table 5 for an abbreviation guide. Of the 
first-line treatments prescribed for the 64 patients diagnosed with H. pylori, the CTA regimen was the 
highest prescribed regimen with 27 patients. This regimen is made up of clarithromycin 500 mg, 
amoxicillin 1 gram, and a PPI of normal or double strength dosage4. All medications are taken twice daily 
for 14 days.  
The second highest treatment for initial therapy was the “Other” category consisting of 19 
patients. This category was made up of all regimens that did not follow the recommendations made in 
the guidelines. The most common regimen in the “Other” category was an MBQ regimen, with 11 
patients. The standard BQ regimen is normally made up of a PPI taken twice a day plus bismuth 
subcitrate or subsalicylate, metronidazole 250-500 mg, and tetracycline 500 mg taken four times a day 
for 10-14 days. In the MBQ regimen the tetracycline is replaced by doxycycline, a derivative of 
tetracycline that has a similar mechanism of action. There were two patients that received PPIs alone; 
the reason documented in the chart for both patients was pregnancy. A complete breakdown of initial 
treatment options can be found in Figure 2.   
Three patients had received a macrolide within 1 year of H. pylori treatment initiation. One 
patient was still prescribed the CTA regimen, one patient received the BQ regimen (non-macrolide 
containing), and one patient received hybrid therapy with clindamycin replacing the clarithromycin 
component. Three patients had received a fluoroquinolone prescription within 1 year of H. pylori 
treatment initiation, and all three were appropriately treated with non-fluoroquinolone containing 
regimens.  
There were 44 identified drug interactions; some patients had one interaction and a select few 
had two interactions. There were 2 interactions where no action was needed (category B), 8 interactions 
Page 13
where increased monitoring was necessary (category C), and 22 interactions where modification should 
have been considered (category D). The most frequent category D interaction was an interaction 
between the tetracycline/doxycycline and bismuth subsalicylate of the BQ and MBQ regimens. Nineteen 
patients received the BQ or MBQ regimens; the interaction populated for each of these patients. There 
were only two interactions in which there was a chance of decreased concentration of an antibiotic. 
Clarithromycin-diazepam was one of these interactions; in this case the patient was only taking as 
needed for seizures. The other interaction was doxycycline and sucralfate, which could have been 
clinically significant. The rest of the interactions were related to increased toxicity of home medications.  
Figure 2.  
First Line Treatments 
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Table 5.  
Abbreviation Guide 
BQ Bismuth quadruple 
MBQ Modified Bismuth quadruple 
CTA Clarithromycin triple w/amoxicillin 
CTM Clarithromycin triple w/metronidazole 
LS Levofloxacin sequential 
LT Levofloxacin triple 
 
Follow-Up and Second-Line Therapy 
 Thirty-five patients out of 64 received follow-up testing after completion of therapy. The urea 
breath test remained the most popular testing method in follow-up therapy with 28 patients, followed 
by 6 patients with fecal antigen testing and 1 patient with a biopsy-based test.  
 Out of the 35 patients who were retested, 11 patients had positive H. pylori test results. 
Curiously, 15 patients were given second-line treatment, which indicates four patients were given 
second-line therapy without being re-tested. Bismuth quadruple was the most common choice for 
second-line therapy with 7 patients. Of the 15 patients prescribed second-line therapy, 11 patients’ 
regimens were deemed appropriate. Complete analysis of second-line therapy can be found in Figure 3.  
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Appropriateness and Success of Therapy 
Overall treatment regimen, treatment duration, follow-up testing procedures, and relevant drug 
interactions were observed on Athena to determine the appropriateness of therapy. Patients who filled 
at St. Vincent’s pharmacy were determined adherent or nonadherent by looking at fill history through 
Enterprise. For patients who filled at an outside pharmacy, presence of insurance claims were relied on 
to determine adherence to the regimen. Absence of an insurance claim from an outside pharmacy was 
deemed not picked up and was considered inappropriate therapy. Any progress notes by providers were 
Figure 3. 
Follow-Up Testing 
Second-Line Therapies 
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also read to look for notes about adherence. Only 15 patients received appropriate therapy out of the 
64 patients who received H. pylori treatment. The biggest determinant of inappropriate therapy for the 
remaining patients was the absence of follow-up testing (30.9% of errors), followed up by adherence 
issues (25% of errors) and an incorrect regimen being prescribed (16.7% of errors). A complete analysis 
can be found in Figure 4.  
 Without taking appropriateness of therapy into account, there were 18 successful treatments 
defined by an appropriate negative follow-up H. pylori test and 15 failed treatments defined by a 
positive follow-up H. pylori test. There were 24 patients whose outcomes could not be determined due 
to lack of follow-up, and there were 7 patients who had negative H. pylori tests taken <4 weeks of 
antibiotic therapy, leaving the possibility of a falsely negative test. This information can also be found in 
Figure 4.  
 
  
 
Figure 4  
Inappropriate Therapy                                                                           Overall Treatment Outcomes 
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Discussion  
 H. pylori infection continues to be a significant issue among patients in the United States. It can 
be a difficult infection to treat, as it has been shown that different countries have varying levels of 
resistance6,8,15. A meta-analysis that looked at treatment eradication rates of the bismuth quadruple and 
clarithromycin triple therapy and found that while the overall eradication rates were 77.6% and 68.9% 
respectively, a high heterogeneity between the trials was found20. In this project, the overall H. pylori 
eradication rate of patients with a known outcome was slightly lower at 54.5%. Of the 8 patients who 
received the BM regimen first-line, 4 had negative H. pylori tests, making the eradication rate lower at 
around 50%. The CTA regimen had an even lower eradication rate of around 37%. When adjusted to 
only include patients with known outcomes, the eradication rates become 80% and 55.6%, respectively. 
While our data was limited by sample size and the amount of patients lost to follow-up and with 
unknown outcomes, this project still provides comparable eradication rates to current data.   
The variety of different treatment options can make it challenging for providers to choose an 
appropriate regimen. The ACG guidelines have a total of eight first-line regimens to choose from, with 
additional regimens developed for salvage therapy. In this project, it was discovered that an incorrect 
regimen was the third highest reason for inappropriate treatment. Some of the incorrect regimens 
contained pieces of the therapy recommended by the ACG but were missing key components. One of 
the biggest misunderstood regimens in this project was the bismuth quadruple regimen, as many 
prescribers substituted doxycycline in place of tetracycline.   
While replacing tetracycline with doxycycline may seem reasonable given their identical 
mechanisms of action and similarities in structure21,22, there are some significant differences in 
doxycycline that may lower effectiveness of the regimen. Tetracycline and doxycycline have differences 
in protein binding; tetracycline has protein binding of about 55%-65%21 while doxycycline is highly 
protein bound at >90%22. This may result in lower concentrations of the drug being systemically 
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absorbed because it is binding to protein in the plasma at a higher degree. Protein-bound drug does not 
have systemic action since it remains in the plasma. While not extensively demonstrated in this project, 
highly protein bound drugs can interact with other highly protein bound drugs and increase the risk of 
toxicity. The bioavailability of doxycycline also becomes reduced at higher stomach pH22. Tetracycline 
does not have this reported effect21. This may be important because these patients will be taking 
concomitant PPIs, which reduce acid production in the stomach and therefore make the stomach 
environment more alkalotic. Concomitant use of these two medications together may result in less 
doxycycline being absorbed and available for treatment of the infection.  
The data on substituting doxycycline for tetracycline is conflicting; a 1992 study found that only 
65% of patients taking a modified bismuth triple therapy (regimen did not include the PPI component) 
achieved eradication of H. pylori compared to 92% of patients taking a traditional regimen containing 
tetracycline (p = 0.004)23,24. There are more recent studies that replace the metronidazole component 
with amoxicillin in addition to replacing tetracycline with doxycycline taken twice a day that have had 
some successful results24-26. However, there is no way to extrapolate this data to use doxycycline with a 
traditional bismuth quadruple regimen containing metronidazole. No head-to-head studies comparing 
bismuth quadruple therapy to a modified bismuth quadruple therapy with doxycycline exist at this time. 
Given the lack of data and the discouraging results using doxycycline with metronidazole in a bismuth 
triple regimen, it may be best practice to avoid replacing tetracycline with doxycycline until additional 
data is published.  
The heterogeneity of eradication rates20 and the variety in resistance rates around the world6,8 
make it difficult to choose an appropriate regimen. Finding recent places of travel in Athena proved to 
be a challenge and place of origin is not consistently documented in Athena, so this project’s 
representation of possible H. pylori infections from other countries is limited and wholly unreliable.  
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However, while countries of origin and travel were difficult to find, need for a translator was 
found to be consistently documented among all patients. As shown in Figure 1., this project’s small 
patient population was extremely diverse, encompassing ten different languages from all over the 
world. At St. Vincent, in-house translators are available for Spanish-speaking patients but for other 
languages, a telephone or video interpreter is used. Historically, patients who receive interpreter 
services in a practice setting overall receive significantly more recommended preventative services, 
made more office visits, and had more prescriptions written and filled27. However, while telephone 
translation is more cost-effective and convenient, problems such as inadequate clarity of sound, inability 
of the interpreter to respond to visual cues from the provider and patient, and cultural barriers in which 
some patients are uncomfortable speaking with an unknown voice28 can impact the effectiveness of 
using the service.  
Language is not the only difference among patients from other countries. There are many 
different cultural factors that may hinder a patient’s adherence. Among minority populations, an 
inherent distrust of the health system may exist due to perceived inequal treatment of minority 
populations29. 
Low socioeconomic class is also another barrier to adherence. Many of the patients in our 
project were self-pay and did not have insurance coverage. Pricing of individual medications can vary 
significantly based on pharmacy, but for someone without insurance tetracycline itself is over $300 for a 
14-day supply30, and a full bismuth quadruple regimen may cost even more. Other patients were 
Medicaid or Medicare patients, which may result in forcing treatment options that are covered instead 
of the ones truly indicated on an individual patient basis.  
Patient understanding is key in multi-drug regimens such as those used in H. pylori treatment, 
and the language barrier and culture can make this treatment even more difficult. In Arab patients, 
there is a belief that obtaining healthcare is important, but ultimately true recovery comes from God31. 
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They may not view the H. pylori regimen as important for eradication as providers or those of other 
cultures, so it is important to respectfully acknowledge this belief and stress the importance of taking 
the complete regimen. In addition, some cultures, particularly Hispanic patients, may view illness as evil 
done by another person or outside source29. This may limit the perceived importance of preventative 
medicine such as follow-up treatment and annual exams. Certain cultures may rely on other herbal or 
alternative medicine therapies29,31, which may interact with components of the antibiotic regimen. For 
instance, both garlic and honey can be used for symptoms of gastritis, but both can interact with 
Cytochrome P 450 (CYP) 3A4 enzyme substrates32,33, such as clarithromycin. This can increase risk of 
toxicity or lower effectiveness if taken together.   
Of all identified adherence issues, 80% occurred with patients who needed a translator. Of 
patients who needed a translator, 76.1% had inappropriate therapy of some kind. Of patients lost to 
follow-up, a vast majority (~88%) required a translator. Translation services are a great start in trying to 
expand healthcare services to non-English speaking patients, but our project showed that it isn’t doing 
quite enough. Options to increase cultural awareness may include involving social work professionals, 
respectfully inquiring the patient about their individual beliefs about health care and treatment, and 
avoiding stereotypes based on age or race29. Staff education about various cultures and their beliefs 
would also be beneficial in better understanding patients’ views of the healthcare system. Overall, a 
more inclusive approach to other cultures healthcare preferences would benefit both the provider and 
the patient.  
 
Weaknesses  
 This project was a retrospective chart review of a small sample size, so it is limited in its capacity 
to expand to other institutions. Because H. pylori has such diverse infection and resistance rates around 
the world, however, it is difficult to establish consistency among multiple locations. The time frame 
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started only one month after the ACG guidelines were released, so there is the possibility that old 
guidance was still being used for treatment decisions.  
 A significant weakness during this study was looking only at whether patients had visited a 
different country within one year of diagnosis. H. pylori can often be asymptomatic for years before 
causing issues for patients4, and a one-year time frame may have been inappropriate in determining 
where their H. pylori infections originated. As mentioned previously, Athena did not have consistent 
reporting of travel habits and patients were not often questioned about them during these visits. In 
addition, there were situations in which a patient may not have been traveling but had family members 
who had multiple risk factors for H. pylori infection. According to the ACG guidelines, if one family 
member has H. pylori, other family members are at higher risk for contracting H. pylori as well1,3-4,9. 
Looking at birth country, race, and socioeconomic status may have been more insightful to determine 
possible contraction location and to explore additional risk factors.  
 
Conclusion 
 While this project was not truly able to assess whether ACG-guideline directed therapy is 
resulting in successful eradication to a large degree, it was able to identify inconsistencies between St. 
Vincent’s treatment habits and the ACG guidelines. Poor follow-up testing is a significant barrier to 
completely eradicating H. pylori and preventing the long-term risks that come with infection.  
 This project was also able to identify that an underserved population makes up the majority of 
H. pylori infection cases. These patients are already at risk of successful treatment and H. pylori 
regimens of multiple drugs several times a day may compound that risk. This project was able to break 
down the main reasons that patients are treated inappropriately and identify potential areas of protocol 
change that can help increase patient’s chances of completely eradicating H. pylori infections. 
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